WT1 and acute myeloid leukemia: In AML, WT1 is considered an oncogene and its expression was found on the majority of AML samples.44 Importantly, higher WT1 gene expression is associated with lower complete remission rates and decreased survival.45 Most therapeutic antibodies recognize intact antigens expressed on the cell surface; however, the majority of leukemia-associated antigens are intracellular.